Search results
Takeda Pharmaceutical Co. (TAK) Upgraded to Buy: What Does It Mean for the Stock?
Zacks via Yahoo Finance· 3 months agoTakeda Pharmaceutical Co. (TAK) might move higher on growing optimism about its earnings prospects,...
Better High-Yield Dividend Stock: Takeda Pharmaceutical vs. Viatris
Motley Fool· 9 months agoIf you're looking for a high-yield dividend stock in the healthcare sector, you might be interested...
Is Takeda Pharmaceutical Co. (TAK) a Great Value Stock Right Now?
Zacks via Yahoo Finance· 10 months agoHere at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and...
Should Value Investors Buy Takeda Pharmaceutical Co. (TAK) Stock?
Zacks via Yahoo Finance· 1 month agoHere at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and...
Got $5,000? These 2 Dividend Stocks Haven't Been This Cheap in Years
Motley Fool· 2 years agoWhen dividend stocks dip in price and go on sale, they can create buying opportunities for long-term...
One Ultra-Cheap High-Yield Dividend Stock to Buy
Motley Fool via Yahoo Finance· 5 months agoDividend stocks that trade at cheap valuations can give investors multiple ways to profit from them. In addition to dividend income, you're also...
ARS Pharmaceuticals, Nuvalent, and More Stocks See Action From Activist Investors
Barrons.com· 2 months ago13D FILINGS These disclosures are from 13Ds filed with the Securities and Exchange Commission. 13Ds...
Takeda shells out $100m to license AC Immune’s Phase II Alzheimer’s therapy
Pharmaceutical Technology via Yahoo Finance· 3 weeks agoJapanese pharma company Takeda has signed an exclusive, worldwide option and licence agreement for...
Takeda's FY22 Net Profit Jumps 38%, But Expects Lower FY23 Revenues
Benzinga via Yahoo Finance· 1 year agoTakeda Pharmaceutical Co Ltd's (NYSE: TAK) FY22 net profit rose 37.8% to ¥317.02 billion, mainly due...
Takeda's Approved Blood Cancer Drug Hits Primary Goal In Newly-Diagnosed Patient Settings
Benzinga via Yahoo Finance· 2 years agoTakeda Pharmaceutical Co Ltd's (NYSE: TAK) Phase 3 PhALLCON trial of Iclusig (ponatinib) met its...